The FDA has issued a new draft guidance intended to assist FDA staff and those in the healthcare industry with submitting investigational device exemption (IDE) applications to conduct clinical trials for neurological medical devices. 

Of more than 1,500 tweets randomly pulled from a qualified starting cohort of more than 15,000 mentioning the term “lung cancer” over two and a half weeks in January 2015, just one lonely tweet linked to a patient recruitment website for a clinical trial.

Performing PET/CT examinations using the radiotracer 18-Fluoro-deoxyglucose (FDG) immediately following localized liver tumor ablation is more effective than contrast-enhanced CT for predicting tumor recurrence, according to results of a study published online in the Journal of Nuclear Medicine.

Johns Hopkins researchers have begun genetically modifying adult cells to create balls of neurons that may serve as “mini-brains,” potentially good for preclinically studying—in petri dishes rather than in animals—Alzheimer’s, Parkinson’s, autism and the effects of drugs, for starters.

When it comes to predicting the cognitive-impairment course Alzheimer’s disease will take in a mildly stricken patient, neither of two tracers commonly used with PET—18F-FDG (for assessing glucose metabolism) and 11C-PiB (for assessing amyloid deposits)—brings much to the table. And that’s so regardless of automated vs. visual analysis.